Defined therapeutic microbiota and methods of use thereof
AssigneeThe Brigham and Women's Hospital, Inc.
InventorsLynn Bry, Georg Gerber, Jessica Allegretti, Richard Lavin, Nicholas DiBenedetto
Life of this patent
Estimating the term…
Abstract
Described herein are methods and compositions for the use of treating and/or preventing Clostridium difficile infections, including recurrent C. difficile infections, in a subject. Aspects of the technology relate to administering to a subject in need thereof a composition comprising a defined therapeutic microbiota comprising, e.g. Clostridial species. Also described herein are biomarker profiles, including a biomarker profile comprising two groups of Clostridial species, that is predictive of the likelihood of recurrent C. difficile infection and/or susceptibility to initial C. difficile infection.
Claims8
A method of suppressing toxin production by C. difficile bacteria in a subject in need thereof, the method comprising orally administering a formulation comprising viable C. scindens and C. bifermentans bacteria in an amount effective to reduce C. difficile toxin by at least 10% as compared to the level of C. difficile toxin prior to treatment onset, wherein one or both of the C. scindens and C. bifermentans bacteria are in spore form or in dried viable form;
- and wherein the formulation comprises no other bacteria.
A method of suppressing toxin production by C. difficile bacteria in a subject in need thereof, the method comprising orally administering a formulation comprising viable C. scindens, C. bifermentans and Ruminococcus obeum bacteria in an amount effective to reduce C. difficile toxin by at least 10% as compared to the level of C. difficile toxin prior to treatment onset,
- wherein the C. scindens, C. bifermentans and R. obeum bacteria are in spore form or in dried viable form.
Dependencies are inferred from the claim text.